BNP Paribas Financial Markets
ORGO icon

BNP Paribas Financial Markets’s Organogenesis Holdings ORGO Stock Holding History

BNP Paribas Financial Markets’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.7K Buy
32,789
+15,465
+89% +$37.8K ﹤0.01% 4678
2026
Q1 		$41.1K Buy
17,324
+1,640
+10% +$5.68K ﹤0.01% 4796
2025
Q4 		$81.2K Buy
15,684
+1,162
+8% +$5.63K ﹤0.01% 4465
2025
Q3 		$61.3K Buy
14,522
+5,273
+57% +$24.5K ﹤0.01% 4511
2025
Q2 		$33.9K Sell
9,249
-94,452
-91% -$352K ﹤0.01% 4393
2025
Q1 		$448K Buy
103,701
+8,648
+9% +$34.9K ﹤0.01% 3250
2024
Q4 		$304K Sell
95,053
-2,864
-3% -$9.61K ﹤0.01% 3620
2024
Q3 		$280K Sell
97,917
-21,645
-18% -$60.7K ﹤0.01% 3112
2024
Q2 		$335K Sell
119,562
-3,824
-3% -$10.3K ﹤0.01% 2859
2024
Q1 		$350K Buy
123,386
+105,078
+574% +$357K ﹤0.01% 3038
2023
Q4 		$74.9K Buy
18,308
+5,542
+43% +$15.5K ﹤0.01% 3463
2023
Q3 		$40.6K Sell
12,766
-5,210
-29% -$16.6K ﹤0.01% 3496
2023
Q2 		$59.7K Sell
17,976
-41,294
-70% -$122K ﹤0.01% 3416
2023
Q1 		$126K Buy
59,270
+23,068
+64% +$57K ﹤0.01% 3267
2022
Q4 		$97.4K Buy
36,202
+548
+2% +$1.6K ﹤0.01% 3264
2022
Q3 		$116K Buy
35,654
+14,240
+66% +$64.3K ﹤0.01% 3709
2022
Q2 		$105K Buy
21,414
+5,212
+32% +$32.1K ﹤0.01% 3341
2022
Q1 		$123K Sell
16,202
-57,666
-78% -$446K ﹤0.01% 3303
2021
Q4 		$683K Sell
73,868
-27,940
-27% -$297K ﹤0.01% 2847
2021
Q3 		$1.45M Buy
101,808
+84,392
+485% +$1.31M ﹤0.01% 2124
2021
Q2 		$289K Buy
17,416
+14,315
+462% +$267K ﹤0.01% 2762
2021
Q1 		$56.5K Sell
3,101
-3,568
-54% -$48.3K ﹤0.01% 3576
2020
Q4 		$50.2K Buy
6,669
+1,792
+37% +$8.51K ﹤0.01% 3552
2020
Q3 		$18.7K Buy
4,877
+2,808
+136% +$11.1K ﹤0.01% 3853
2020
Q2 		$7.95K Sell
2,069
-1,397
-40% -$5.04K ﹤0.01% 3803
2020
Q1 		$11.2K Buy
3,466
+1,221
+54% +$5.23K ﹤0.01% 4011
2019
Q4 		$10.8K Buy
2,245
+1,724
+331% +$10.9K ﹤0.01% 4119
2019
Q3 		$3.42K Buy
521
+494
+1,830% +$2.75K ﹤0.01% 4314
2019
Q2 		$205 Buy
+27
New +$199 ﹤0.01% 4455

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

BNP Paribas Financial Markets's ORGO Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Organogenesis Holdings (ORGO) stake by 89% in Q2 2026, buying an estimated $37.8K and bringing the position to 32,789 shares worth $79.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4678.

BNP Paribas Financial Markets first reported a position in ORGO in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.45M in Q3 2021. 125 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • BNP Paribas Financial Markets held 32,789 shares of Organogenesis Holdings worth $79.7K as of Q2 2026.
  • BNP Paribas Financial Markets bought 15,465 Organogenesis Holdings shares in Q2 2026, an estimated $37.8K.
  • Organogenesis Holdings made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4678 holding.
  • BNP Paribas Financial Markets first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's Organogenesis Holdings position peaked at $1.45M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.